DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
1404
PAMLECTABART TISMANITIN
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
PAMLECTABART TISMANITIN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ANZURSTOBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
ANZURSTOBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SPEVATAMIG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
SPEVATAMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MAB-425
2
Antibody
Investigational
Unknown
Unknown
Glioma
Epidermal growth factor receptor erbB1 inhibitor
MAB-425
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GSK-2330811
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
GSK-2330811
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ADUCANUMAB
2
Antibody
Investigational
Unknown
Unknown
Alzheimer Disease
Beta amyloid A4 protein binding agent
ADUCANUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
105J35OE21
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PLOZALIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Melanoma; Atherosclerosis; Cardiovascular Diseases; Diabetic Nephropathies; Multiple Sclerosis
C-C chemokine receptor type 2 inhibitor
PLOZALIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
4XG66BMN0D
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ENOKIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Asthma
Interleukin-9 inhibitor
ENOKIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
I4BE5F78HR
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OBEROTATUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
OBEROTATUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VIBOSTOLIMAB
2
Antibody
Investigational
Unknown
Unknown
Melanoma; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Non-Small-Cell Lung
T-cell immunoreceptor with Ig and ITIM domains antagonist
VIBOSTOLIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
5XO3JF0FEK
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IZENIVETMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
IZENIVETMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TOVECIMIG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
TOVECIMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FLOTETUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute
Interleukin-3 receptor subunit alpha binding agent
FLOTETUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
0AHT0IC02G
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ERTUMAXOMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Breast Neoplasms
Receptor protein-tyrosine kinase erbB-2 cross-linking agent
ERTUMAXOMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
L5L45YGP1O
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NELISTOTUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
NELISTOTUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BECOTATUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
BECOTATUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ALSEVALIMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
ALSEVALIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IMCIROMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
IMCIROMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TREGALIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Psoriasis
T-cell surface antigen CD4 agonist
TREGALIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
43D26MK176
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AME-133V
2
Antibody
Investigational
Unknown
Unknown
Lymphoma, Non-Hodgkin
Integrin beta-2 inhibitor
AME-133V
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ALXN1007
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
ALXN1007
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CREXAVIBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
CREXAVIBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GSK-679586A
2
Antibody
Investigational
Unknown
Unknown
Asthma
Unknown
GSK-679586A
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OPICINUMAB
2
Antibody
Investigational
Unknown
Unknown
Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Optic Neuritis
Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 inhibitor
OPICINUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
WX1WTN0Y15
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DENECIMIG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
DENECIMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMG-108
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Diabetes Mellitus; Osteoarthritis
Interleukin-1 receptor antagonist
AMG-108
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PG-102
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Psoriatic
Tumor necrosis factor receptor superfamily member 5 inhibitor
PG-102
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VEREKITUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
VEREKITUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ONCOLYSIN CD6
2
Antibody
Investigational
Unknown
Unknown
Unknown
T-cell differentiation antigen CD6 binding agent
ONCOLYSIN CD6
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SAMATATUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
SAMATATUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IMZOKITUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
IMZOKITUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VX15
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
VX15
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ORDESEKIMAB
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Celiac Disease; Psoriasis; Vitiligo
Interleukin-15 inhibitor
ORDESEKIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PODENTAMIG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
PODENTAMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MIBAVADEMAB
2
Antibody
Investigational
Unknown
Unknown
Lipodystrophy, Congenital Generalized
Unknown
MIBAVADEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
18
19
20
21
22
23
24
…
40
41
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA